Zimmer Biomet has agreed to acquire Iovera nerve therapy technology from Pacira BioSciences for a total value of up to $140 million. The deal includes an upfront payment of $70 million, with the remainder consisting of potential revenue-based milestone payments scheduled through December 31, 2031....
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) is a U.S.-based medical device company with a market capitalization of $18.01 billion, specializing in orthopedic reconstructive products. The stock is currently trading at $93.1, showing a modest 2.14 point increase or 0.02% change, and sits slightly above its...
Zimmer Biomet (ZBH) is currently trading on the NYSE within a defined technical range, with shares fluctuating between a support level of approximately $84.56 and a resistance level near $93.58. Recent price data indicates the stock closed around $90.57 on June 24, 2026, reflecting a...
ZBH (NYSE) insider Suketu Upadhyay executed two proposed sales of common stock in May 2026, as reported on a Form 144 filed with the SEC. The first transaction occurred on May 12, 2026, involving the sale of 31,252 shares for a total gross proceeds of...
Zimmer Biomet has updated its conflict-of-interest disclosures regarding its partnership with the National Football League, confirming that Dr. Elliot Pellman, the New York Jets team doctor, serves as a consultant to the orthopedics group. This disclosure highlights the company's continued visibility and active role in...
Zimmer Biomet Holdings, Inc. (ZBH) is a leading global orthopedic device manufacturer headquartered in Warsaw, Indiana, formed by the 2015 merger of Zimmer and Biomet. The company supplies implants, instruments, and digital tools for joint reconstruction to surgeons and hospitals in over 100 countries, with...
Zimmer Biomet Holdings (ZBH) has announced an expanded share repurchase program authorizing up to US$1.00 billion of common stock for fiscal 2026, alongside a declared quarterly cash dividend of US$0.24 per share. The company recently reported quarterly results that exceeded earlier expectations and subsequently raised...
Zimmer Biomet Holdings, Inc. (ZBH) is a large-cap medical technology company with a market capitalization of $17.1 billion, specializing in orthopedic implants and surgical products across over 100 countries. The company benefits from an aging demographic driving demand for mobility solutions and maintains strong relationships...
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) announced on May 22, 2026, that its Board of Directors has approved a quarterly cash dividend for the second quarter of 2026. The dividend amount is set at $0.24 per share, which will be payable to stockholders...
Zimmer Biomet stock rose approximately 4.9% in the afternoon session after the company announced an increase in its share repurchase expectations for fiscal year 2026. The medical device manufacturer now plans to buy back up to $1 billion of common stock, representing a $250 million...
Zimmer Biomet has released its executive compensation disclosures for fiscal year 2025, highlighting a double-digit increase in median employee pay alongside specific packages for top leadership. The world’s 18th-largest medical device company reported revenue of $8.23 billion in 2025, representing a 7% year-over-year increase from...
Zimmer Biomet, an orthopedic device manufacturer based in Warsaw, Indiana, has announced an increase in its planned share repurchase program for the remainder of fiscal 2026. The company now expects to repurchase up to $1 billion of its common stock by the end of the...
Zimmer Biomet Holdings, Inc. announced on May 12, 2026, that it is increasing its expectation for share repurchases for fiscal year 2026 to up to $1 billion. This represents a significant increase of $250 million from the company's previous assumption regarding annual buybacks. The repurchase...
This article evaluates the earnings quality of Zimmer Biomet Holdings (NYSE: ZBH), concluding that despite disappointing statutory profit figures, the underlying income statement quality appears strong. The report highlights that statutory profits were reduced by US$286 million over the last twelve months due to unusual...
Zimmer Biomet's first quarter of 2026 results surpassed Wall Street expectations for both revenue and non-GAAP earnings, though the market reaction remained negative. The company reported revenue of $2.09 billion, a slight beat over analyst estimates of $2.07 billion and representing 9.3% year-on-year growth, while...
The provided article titled "Zimmer Biomet Buzz Grows Across NYSE Composite Trend" appears to be a promotional landing page rather than a substantive news report on Zimmer Biomet (ZBH). The text lists several unrelated headlines, including questions about Stellantis earnings, Weyerhaeuser gains, WisdomTree AUM growth,...
Zimmer Biomet Holdings Inc., trading on NYSE and SIX under ticker ZBH, announced its first quarter financial results for the period ended March 31, 2026, reporting significant growth across multiple key metrics. First quarter net sales reached $2.087 billion, representing a 9.3% increase on a...
On Tuesday, Wall Street's three major indices closed in the red as investors reacted to a wave of negative corporate news, with the Nasdaq leading the decline at 0.90 percent, followed by the S&P 500 down 0.49 percent and the Dow Jones dipping 0.05 percent....
Zimmer Biomet Holdings (NYSE:ZBH) is approaching its ex-dividend date, with shareholders needing to purchase shares before March 31st to receive the upcoming dividend payment scheduled for April 30th. The company will distribute US$0.24 per share, bringing the total annualized payout to US$0.96 based on the...
Zimmer Biomet (ZBH) is currently positioned with a Zacks Rank of #3, indicating a "Hold" rating, and has seen its stock decline by 22% over the past year, underperforming the broader S&P 500 which grew 18.3% while significantly outpacing the industry's 20.5% fall. The company...
